
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3022217/publications.pdf Version: 2024-02-01



YUE-IIN YANG

#	Article	IF	CITATIONS
1	Prevalence, Predictors, and Impact of Coronary Artery Ectasia in Patients With Atherosclerotic Heart Disease. Angiology, 2023, 74, 47-54.	0.8	3
2	Prognostic and Practical Validation of ESC/EACTS High Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary PCI Patients. Journal of Atherosclerosis and Thrombosis, 2022, 29, 502-526.	0.9	4
3	Immediate Versus Staged Multivessel PCI Strategies in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Systematic Review and Meta-Analysis. American Journal of the Medical Sciences, 2022, 363, 161-173.	0.4	1
4	Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction. Cardiovascular Research, 2022, 118, 2165-2178.	1.8	24
5	The PRECISE-DAPT score and 5-year outcomes after percutaneous coronary intervention: a large-scale, real-world study from China. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 812-820.	1.8	6
6	Sequential transplantation of exosomes and mesenchymal stem cells pretreated with a combination of hypoxia and Tongxinluo efficiently facilitates cardiac repair. Stem Cell Research and Therapy, 2022, 13, 63.	2.4	19
7	Protective ballooning technique for prevention of side branch occlusion in coronary nonleft main true bifurcation lesions: A singleâ€center study. Catheterization and Cardiovascular Interventions, 2022, , .	0.7	1
8	The optimal percutaneous coronary intervention strategy for patients with ST-segment elevation myocardial infarction and multivessel disease: a pairwise and network meta-analysis. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210780.	1.1	1
9	High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort. Cardiovascular Diabetology, 2022, 21, 46.	2.7	27
10	Thyroid hormones inhibit apoptosis of macrophage induced by oxidized lowâ€density lipoprotein. BioFactors, 2022, 48, 86-99.	2.6	3
11	Adiponectin improves the therapeutic efficacy of mesenchymal stem cells by enhancing their engraftment and survival in the peri-infarct myocardium through the AMPK pathway American Journal of Translational Research (discontinued), 2022, 14, 534-553.	0.0	0
12	New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study. Circulation: Cardiovascular Interventions, 2022, 15, 101161CIRCINTERVENTIONS121011536.	1.4	12
13	Stress hyperglycemia ratio and longâ€ŧerm mortality after acute myocardial infarction in patients with and without diabetes: A prospective, nationwide, and multicentre registry. Diabetes/Metabolism Research and Reviews, 2022, 38, .	1.7	20
14	Effect of Cheese Intake on Cardiovascular Diseases and Cardiovascular Biomarkers. Nutrients, 2022, 14, 2936.	1.7	25
15	Tongxinluo-pretreated mesenchymal stem cells facilitate cardiac repair via exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway. Stem Cell Research and Therapy, 2022, 13, .	2.4	25
16	Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI. Platelets, 2021, 32, 533-541.	1.1	4
17	The pivotal roles of exosomes derived from endogenous immune cells and exogenous stem cells in myocardial repair after acute myocardial infarction. Theranostics, 2021, 11, 1046-1058.	4.6	67
18	Predictors for adverse outcomes of patients with recanalized chronic total occlusion lesion. European Journal of Clinical Investigation, 2021, 51, e13368.	1.7	3

#	Article	IF	CITATIONS
19	Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus. American Journal of Cardiology, 2021, 142, 14-24.	0.7	2
20	Appropriateness of gastrointestinal prophylaxis use during hospitalization in patients with acute myocardial infarction: Analysis from the China Acute Myocardial Infarction Registry. Clinical Cardiology, 2021, 44, 43-50.	0.7	3
21	Effect of Baseline Thrombocytopenia on Long-Term Outcomes in Patients With Acute ST-Segment Elevated Myocardial Infarction ― A Large Propensity Score-Matching Analysis From the China Acute Myocardial Infarction (CAMI) Registry ―. Circulation Journal, 2021, 85, 150-158.	0.7	2
22	Long-Term Clinical Outcomes of Unprotected Left Main Percutaneous Coronary Intervention: A Large Single-Centre Experience. Journal of Interventional Cardiology, 2021, 2021, 1-10.	0.5	6
23	Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases. Gut Microbes, 2021, 13, 1936379.	4.3	24
24	Long-Term Outcomes of Single-Vessel Percutaneous Coronary Intervention on Culprit Vessel vs. Multivessel Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Multivessel Coronary Artery Disease. Circulation Journal, 2021, 85, 185-193.	0.7	1
25	Association of Acute Procedural Results With Long-Term Outcomes After CTO PCI. JACC: Cardiovascular Interventions, 2021, 14, 278-288.	1.1	22
26	Predicting 2â€year allâ€cause mortality after contemporary <scp>PCI</scp> : Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	0.7	6
27	Longâ€ŧerm clinical outcomes in transradial versus transfemoral access for left main percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 97, 1009-1015.	0.7	0
28	The 11-Year Prognostic Impact of Chronic Total Occlusion in the Noninfarct-Related Coronary Artery on Patients with Acute Myocardial Infarction. Journal of Interventional Cardiology, 2021, 2021, 1-8.	0.5	5
29	Association of symptom status, myocardial viability, and clinical/anatomic risk on longâ€ŧerm outcomes after chronic total occlusion percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 97, 996-1008.	0.7	3
30	The Vital Roles of Mesenchymal Stem Cells and the Derived Extracellular Vesicles in Promoting Angiogenesis After Acute Myocardial Infarction. Stem Cells and Development, 2021, 30, 561-577.	1.1	13
31	A Fluorescence Assay for Evaluating the Permeability of a Cardiac Microvascular Endothelial Barrier in a Rat Model of Ischemia/reperfusion. Journal of Visualized Experiments, 2021, , .	0.2	3
32	Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. Cardiovascular Diabetology, 2021, 20, 143.	2.7	22
33	Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis, 2021, 28, 873-882.	0.9	7
34	5-Year Clinical Outcomes of Successful Recanalisation for Coronary Chronic Total Occlusions in Patients With or Without Type 2 Diabetes Mellitus. Frontiers in Cardiovascular Medicine, 2021, 8, 691641.	1.1	2
35	Clinical Characteristics, Prognosis, and Gender Disparities in Young Patients With Acute Myocardial Infarction. Frontiers in Cardiovascular Medicine, 2021, 8, 720378.	1.1	16
36	Implications of Periprocedural Myocardial Biomarker Elevations and Commonly Used MI Definitions After Left Main PCI. JACC: Cardiovascular Interventions, 2021, 14, 1623-1634.	1.1	27

#	Article	IF	CITATIONS
37	The Clinical Impact of Proton Pump Inhibitors When Co-Administered With Dual Antiplatelet Therapy in Patients Having Acute Myocardial Infarction With Low Risk of Gastrointestinal Bleeding: Insights From the China Acute Myocardial Infarction Registry. Frontiers in Cardiovascular Medicine, 2021, 8, 685072.	1.1	5
38	Length of Stay and Short-Term Outcomes in Patients with ST-Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: Insights from the China Acute Myocardial Infarction Registry. International Journal of General Medicine, 2021, Volume 14, 5981-5991.	0.8	3
39	Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction. International Journal of Nanomedicine, 2021, Volume 16, 6719-6747.	3.3	19
40	Identification of Potential Risk Genes and the Immune Landscape of Idiopathic Pulmonary Arterial Hypertension via Microarray Gene Expression Dataset Reanalysis. Genes, 2021, 12, 125.	1.0	7
41	Effects of metabolic syndrome on onset age and long-term outcomes in patients with acute coronary syndrome. World Journal of Emergency Medicine, 2021, 12, 36.	0.5	6
42	Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China. Frontiers in Cardiovascular Medicine, 2021, 8, 736466.	1.1	6
43	Does Prior Stroke Predict Long-Term Recurrent Stroke After Percutaneous Coronary Intervention? Five-Year Results From a Large Cohort Study. Frontiers in Neurology, 2021, 12, 740136.	1.1	2
44	Comparison of outcomes for percutaneous coronary intervention in men and women with unprotected left main disease. Journal of Geriatric Cardiology, 2021, 18, 168-174.	0.2	1
45	Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 768190.	1.1	4
46	Genetic Predisposition to Low-Density Lipoprotein Cholesterol May Increase Risks of Both Individual and Familial Alzheimer's Disease. Frontiers in Medicine, 2021, 8, 798334.	1.2	7
47	Current Status and Hospital-Level Differences in Care and Outcomes of Patients With Acute Non-ST-Segment Elevation Myocardial Infarction in China: Insights From China Acute Myocardial Infarction Registry. Frontiers in Cardiovascular Medicine, 2021, 8, 800222.	1.1	2
48	Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Global Heart, 2021, 16, 89.	0.9	2
49	Integrated Gene Expression Profiling Analysis Reveals Potential Molecular Mechanisms and Candidate Biomarkers for Early Risk Stratification and Prediction of STEMI and Post-STEMI Heart Failure Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 736497.	1.1	9
50	Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19. Cardiovascular Research, 2020, 116, 353-367.	1.8	213
51	Impact of unknown diabetes and prediabetes on clinical outcomes in "nondiabetic―Chinese patients after a primary coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 644-651.	1.1	8
52	Integrating the residual SYNTAX score to improve the predictive ability of the age, creatinine, and ejection fraction (ACEF) score for cardiac mortality in percutaneous coronary intervention patients. Catheterization and Cardiovascular Interventions, 2020, 95, 534-541.	0.7	6
53	Lipoprotein(a) levels are associated with coronary severity but not with outcomes in Chinese patients underwent percutaneous coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 265-273.	1.1	17
54	Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia/Reperfusion injury. Theranostics, 2020, 10, 11754-11774.	4.6	37

#	Article	IF	CITATIONS
55	Implications of gut microbiome on coronary artery disease. Cardiovascular Diagnosis and Therapy, 2020, 10, 869-880.	0.7	17
56	NFAT activating protein with ITAM motif 1 (NFAM1) is upregulated on circulating monocytes in coronary artery disease and potentially correlated with monocyte chemotaxis. Atherosclerosis, 2020, 307, 39-51.	0.4	3
57	Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention. Chinese Medical Journal, 2020, 133, 2674-2681.	0.9	3
58	The Prevalence of Familial Hypercholesterolemia (FH) in Chinese Patients With Acute Myocardial Infarction (AMI): Data From Chinese Acute Myocardial Infarction (CAMI) Registry. Frontiers in Cardiovascular Medicine, 2020, 7, 113.	1.1	4
59	China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial. American Heart Journal, 2020, 227, 47-55.	1.2	11
60	Prognostic significance of occlusion length in recanalized chronic total occlusion lesion: a retrospective cohort study with 5-year follow-up. BMJ Open, 2020, 10, e038302.	0.8	5
61	Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention. Current Medical Research and Opinion, 2020, 36, 1739-1745.	0.9	10
62	Tongxinluo attenuates oxygen-glucose-serum deprivation/restoration-induced endothelial barrier breakdown via peroxisome proliferator activated receptor-α/angiopoietin-like 4 pathway in high glucose-incubated human cardiac microvascular endothelial cells. Medicine (United States), 2020, 99, e21821.	0.4	6
63	Active SB-P Versus Conventional Approach to the Protection of High-RiskÂSide Branches. JACC: Cardiovascular Interventions, 2020, 13, 1112-1122.	1.1	11
64	Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study. Journal of Interventional Cardiology, 2020, 2020, 1-10.	0.5	7
65	Potential genes and pathways along with immune cells infiltration in the progression of atherosclerosis identified via microarray gene expression dataset re-analysis. Vascular, 2020, 28, 643-654.	0.4	21
66	Strengthening effects of bone marrow mononuclear cells with intensive atorvastatin in acute myocardial infarction. Open Heart, 2020, 7, e001139.	0.9	9
67	D-dimer as a thrombus biomarker for predicting 2-year mortality after percutaneous coronary intervention. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232090430.	1.1	18
68	CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic. Circulation, 2020, 141, e810-e816.	1.6	92
69	Validation of bifurcation DEFINITION criteria and comparison of stenting strategies in true left main bifurcation lesions. Scientific Reports, 2020, 10, 10461.	1.6	12
70	Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI. BMC Cardiovascular Disorders, 2020, 20, 313.	0.7	5
71	Evaluation of a risk index for predicting shortâ€ŧerm and longâ€ŧerm outcomes in patients with STâ€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2020, 95, 542-549.	0.7	1
72	Prognostic value of the GRACE discharge score for predicting the mortality of patients with stable coronary artery disease who underwent percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2020, 95, 550-557.	0.7	2

#	Article	IF	CITATIONS
73	Percutaneous transluminal angioplasty with selective stenting for the treatment of renal artery stenosis caused by fibromuscular dysplasia: 18 years' experience from the China Center for Cardiovascular Disease. Catheterization and Cardiovascular Interventions, 2020, 95, 641-647.	0.7	8
74	Association of <i>β</i> -Blocker Therapy at Discharge with Clinical Outcomes after Acute Coronary Syndrome in Patients without Heart Failure. Cardiovascular Therapeutics, 2020, 2020, 1-10.	1.1	5
75	Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk "TWILIGHT-like―Patients With Diabetes Mellitus. Frontiers in Cardiovascular Medicine, 2020, 7, 586491.	1.1	3
76	Impact of proton pump inhibitors on clinical outcomes in patients after acute myocardial infarction: a propensity score analysis from China Acute Myocardial Infarction (CAMI) registry. Journal of Geriatric Cardiology, 2020, 17, 659-665.	0.2	4
77	LncRNA NKILA was upregulated in diabetic cardiomyopathy with early prediction values. Experimental and Therapeutic Medicine, 2019, 18, 1221-1225.	0.8	8
78	Prognostic Significance of In-hospital Acquired Thrombocytopenia in Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. American Journal of the Medical Sciences, 2019, 358, 19-25.	0.4	3
79	Combinatorial treatment of acute myocardial infarction using stem cells and their derived exosomes resulted in improved heart performance. Stem Cell Research and Therapy, 2019, 10, 300.	2.4	90
80	Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961985363.	0.7	3
81	Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction. Stem Cells Translational Medicine, 2019, 8, 1068-1083.	1.6	34
82	Association of Baseline Smoking Status with Long-Term Prognosis in Patients Who Underwent Percutaneous Coronary Intervention: Large Single-Center Data. Journal of Interventional Cardiology, 2019, 2019, 1-9.	0.5	4
83	Validating the Performance of 5 Risk Scores for Major Adverse Cardiac Events in Patients Who Achieved Complete Revascularization After Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2019, 35, 1058-1068.	0.8	9
84	Association between smoking and in-hospital mortality in patients with acute myocardial infarction: results from a prospective, multicentre, observational study in China. BMJ Open, 2019, 9, e030252.	0.8	9
85	Transplantation efficacy of autologous bone marrow mesenchymal stem cells combined with atorvastatin for acute myocardial infarction (TEAM-AMI): rationale and design of a randomized, double-blind, placebo-controlled, multi-center, Phase II TEAM-AMI trial. Regenerative Medicine, 2019, 14, 1077-1087.	0.8	12
86	Evaluation of a novel score for predicting 2-year outcomes in patients with acute coronary syndrome after percutaneous coronary intervention. Journal of the Chinese Medical Association, 2019, 82, 616-622.	0.6	5
87	Impact of unprotected left main percutaneous coronary intervention on long-term clinical outcomes. Coronary Artery Disease, 2019, 30, 249-254.	0.3	1
88	Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous coronary intervention. Chinese Medical Journal, 2019, 132, 914-921.	0.9	9
89	Angiographic characteristics and in-hospital mortality among patients with ST-segment elevation myocardial infarction presenting without typical chest pain. Chinese Medical Journal, 2019, 132, 2286-2291.	0.9	7
90	Safety and feasibility of simultaneous endovascular therapy for supraâ€arch multivessel stenosis in 256 Chinese patients. Catheterization and Cardiovascular Interventions, 2019, 93, 846-850.	0.7	1

#	ARTICLE	IF	CITATIONS
91	Effect of prior stroke on longâ€term outcomes of percutaneous coronary interventions in Chinese patients: A large singleâ€center study. Catheterization and Cardiovascular Interventions, 2019, 93, E75-E80.	0.7	3
92	Impact of baseline estimated glomerular filtration rate on inhospital outcomes of patients with STâ€elevation myocardial infarction undergoing primary percutaneous coronary intervention: A China acute myocardial infarction registry study. Catheterization and Cardiovascular Interventions, 2019, 93, 793-799.	0.7	4
93	Effect of aortic arch type on technical indicators in patients undergoing carotid artery stenting. Journal of International Medical Research, 2019, 47, 682-688.	0.4	21
94	Simple risk score based on the China Acute Myocardial Infarction registry for predicting in-hospital mortality among patients with non-ST-segment elevation myocardial infarction: results of a prospective observational cohort study. BMJ Open, 2019, 9, e030772.	0.8	6
95	Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging, 2019, 11, 7948-7960.	1.4	33
96	Two-year prognostic value of mean platelet volume in patients with diabetes and stable coronary artery disease undergoing elective percutaneous coronary intervention. Cardiology Journal, 2019, 26, 138-146.	0.5	10
97	A Propensity Score Matching Analysis of Transradial Versus Transfemoral Approaches in Octogenarians Undergoing Percutaneous Coronary Intervention. Acta Cardiologica Sinica, 2019, 35, 301-307.	0.1	5
98	Clinical significance of diabetes on symptom and patient delay among patients with acute myocardial infarction-an analysis from China Acute Myocardial Infarction (CAMI) registry. Journal of Geriatric Cardiology, 2019, 16, 395-400.	0.2	4
99	Combined therapy with atorvastatin and atorvastatin-pretreated mesenchymal stem cells enhances cardiac performance after acute myocardial infarction by activating SDF-1/CXCR4 axis. American Journal of Translational Research (discontinued), 2019, 11, 4214-4231.	0.0	10
100	Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity. Circulation, 2018, 137, 2231-2245.	1.6	68
101	Comparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China. JAMA Internal Medicine, 2018, 178, 239.	2.6	34
102	Carotid artery stenting followed by open heart surgery in 323 patients: Oneâ€year results and influencing factors. Catheterization and Cardiovascular Interventions, 2018, 91, 632-638.	0.7	6
103	Stenting for middle aortic syndrome caused by Takayasu arteritisâ€immediate and longâ€term outcomes. Catheterization and Cardiovascular Interventions, 2018, 91, 623-631.	0.7	19
104	Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drugâ€eluting stent implantations. Catheterization and Cardiovascular Interventions, 2018, 91, 573-581.	0.7	21
105	Changes in characteristics, risk factors, and in-hospital mortality among patients with acute myocardial infarction in the capital of China over 40†years. International Journal of Cardiology, 2018, 265, 30-34.	0.8	13
106	Severe Symptomatic Bicuspid and Tricuspid Aortic Stenosis in China: Characteristics and Outcomes of Transcatheter Aortic Valve Replacement with the Venus-A Valve. Structural Heart, 2018, 2, 60-68.	0.2	18
107	Sexâ€based differences in bleeding and longâ€ŧerm adverse events after percutaneous coronary intervention in older patients with coronary artery disease. Journal of Interventional Cardiology, 2018, 31, 345-352.	0.5	4
108	Impact of Diabetes Mellitus on Percutaneous Coronary Intervention in Chinese Patients: A Large Single-Center Data. Angiology, 2018, 69, 540-547.	0.8	11

#	Article	IF	CITATIONS
109	A New Risk Factor Profile for Contrast-Induced Acute Kidney Injury in Patients Who Underwent an Emergency Percutaneous Coronary Intervention. Angiology, 2018, 69, 523-531.	0.8	12
	Effect of sex difference in clinical presentation (stable coronary artery disease vs unstable angina) Tj ETQq0 0 0	rgBT /Ove	rlock 10 Tf 50
110	outcomes in patients undergoing percutaneous coronary intervention. Journal of Interventional Cardiology, 2018, 31, 5-14.	0.5	17
111	Usefulness of the SYNTAX score II to validate 2â€year outcomes in patients with complex coronary artery disease undergoing percutaneous coronary intervention: A large singleâ€center study. Catheterization and Cardiovascular Interventions, 2018, 92, 40-47.	0.7	15
112	Relationship between High Level of Estimated Glomerular Filtration Rate and Contrast-Induced Acute Kidney Injury in Patients who Underwent an Emergency Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 2041-2048.	0.9	4
113	Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome. Chinese Medical Journal, 2018, 131, 1397-1405.	0.9	0
114	Impact of Residual SYNTAX Score and Its Derived Indexes on Clinical Outcomes after Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 1390-1396.	0.9	3
115	Validation of Predictive Value of Patterns of Nonadherence to Antiplatelet Regimen in Stented Patients Thrombotic Risk Score in Chinese Population Undergoing Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 2699-2704.	0.9	8
116	Evaluation of the Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Bleeding Score for Predicting the Long-term Out-of-hospital Bleeding Risk in Chinese Patients after Percutaneous Coronary Intervention. Chinese Medical Journal, 2018, 131, 1406-1411.	0.9	4
117	Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions. Chinese Medical Journal, 2018, 131, 262-267.	0.9	3
118	Clinical outcomes and influencing factors of in-stent restenosis after stenting for symptomatic stenosis of the vertebral V1 segment. Journal of Vascular Surgery, 2018, 68, 1406-1413.	0.6	13
119	Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 122, 2043-2048.	0.7	15
120	A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation. Journal of Visualized Experiments, 2018, , .	0.2	10
121	A Comparison of Transradial and Transfemoral Percutaneous Coronary Intervention in Chinese Women Based on a Propensity Score Analysis. Korean Circulation Journal, 2018, 48, 719.	0.7	3
122	Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study. Cardiovascular Diabetology, 2018, 17, 114.	2.7	8
123	Nephrotoxicity of iodixanol versus iopamidol in patients undergoing peripheral angiography with or without endovascular therapy. International Urology and Nephrology, 2018, 50, 1879-1886.	0.6	4
124	The CAMI-score: A Novel Tool derived From CAMI Registry to Predict In-hospital Death among Acute Myocardial Infarction Patients. Scientific Reports, 2018, 8, 9082.	1.6	11
125	Tongxinluo attenuates reperfusion injury in diabetic hearts by angiopoietin-like 4-mediated protection of endothelial barrier integrity via PPAR-1± pathway. PLoS ONE, 2018, 13, e0198403.	1.1	16
126	5-Year Safety and Efficacy of ResoluteÂZotarolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2017, 10, 247-254.	1.1	25

#	Article	IF	CITATIONS
127	Tongxinluo exerts protective effects via antiâ€apoptotic and proâ€autophagic mechanisms by activating AMPK pathway in infarcted rat hearts. Experimental Physiology, 2017, 102, 422-435.	0.9	31
128	Subclavian artery stenting for coronaryâ€subclavian steal syndrome. Catheterization and Cardiovascular Interventions, 2017, 89, 601-608.	0.7	7
129	Impact of completeness of revascularization in complex coronary artery disease as measured with the SYNTAX revascularization index: An SEEDS Substudy. Catheterization and Cardiovascular Interventions, 2017, 89, 541-548.	0.7	5
130	Endovascular therapy for Angioâ€seal <sup>TM</sup> â€related acute limb ischemia: Perioperative and longâ€term results. Catheterization and Cardiovascular Interventions, 2017, 89, 609-615.	0.7	1
131	Association of body mass index with mortality in Chinese patients after percutaneous coronary intervention: A large singleâ€center data. Cardiovascular Therapeutics, 2017, 35, e12271.	1.1	7
132	Predictive value of inflammatory factors on contrastâ€induced acute kidney injury in patients who underwent an emergency percutaneous coronary intervention. Clinical Cardiology, 2017, 40, 719-725.	0.7	63
133	Quantitative Proteomics Analysis of Ischemia/Reperfusion Injury-Modulated Proteins in Cardiac Microvascular Endothelial Cells and the Protective Role of Tongxinluo. Cellular Physiology and Biochemistry, 2017, 41, 1503-1518.	1.1	25
134	Long-term outcomes of coronary artery bypass grafting versus percutaneous coronary intervention for Takayasu arteritis patients with coronary artery involvement. Seminars in Arthritis and Rheumatism, 2017, 47, 247-252.	1.6	38
135	Comparison of Transradial and Transfemoral Approaches in Women Undergoing Percutaneous Coronary Intervention in China: A Retrospective Observational Study. Angiology, 2017, 68, 799-806.	0.8	8
136	Prognostic Value of the Clinical SYNTAX Score on 2-Year Outcomes in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 119, 1493-1499.	0.7	12
137	Effect of coronary dominance on 2â€year outcomes after percutaneous coronary intervention in patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2017, 89, 549-554.	0.7	4
138	Plasma big endothelin-1 and stent thrombosis: An observational study in patients undergoing percutaneous coronary intervention in China. Thrombosis Research, 2017, 159, 5-12.	0.8	8
139	Comparison between imported versus domestic drugâ€eluting stents in China: A large singleâ€eenter data. Journal of Interventional Cardiology, 2017, 30, 338-346.	0.5	2
140	Exosomes: promising sacks for treating ischemic heart disease?. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H508-H523.	1.5	27
141	Intravascular Ultrasound Guidance Improves the Long-term Prognosis in Patients with Unprotected Left Main Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Scientific Reports, 2017, 7, 2377.	1.6	23
142	Risk Factors of Contrast-induced Acute Kidney Injury in Patients Undergoing Emergency Percutaneous Coronary Intervention. Chinese Medical Journal, 2017, 130, 45-50.	0.9	25
143	Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1. Frontiers in Pharmacology, 2017, 8, 775.	1.6	33
144	Elevated plasma miRNA-122, -140-3p, -720, -2861, and -3149 during early period of acute coronary syndrome are derived from peripheral blood mononuclear cells. PLoS ONE, 2017, 12, e0184256.	1.1	25

#	Article	IF	CITATIONS
145	Readthrough of SCN5A Nonsense Mutations p.R1623X and p.S1812X Questions Gene-therapy in Brugada Syndrome. Current Gene Therapy, 2017, 17, 50-58.	0.9	5

## 146 ä,国è€å¹´æ,£è€...ç»æjj动è,,‰ä,Žè,j动è,,‰ä»<å...¥æ²»ç—比较. Chinese Medical Sciences Journal, 2017, 32).⊉61-1702

147	An unrecognised presentation of Takayasu arteritis: superficial femoral artery involvement. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 83-87.	0.4	5
148	Percutaneous Ventricular Restoration Therapy Using the Parachute Device in Chinese Patients with Ischemic Heart Failure. Chinese Medical Journal, 2016, 129, 2058-2062.	0.9	13
149	Stenting for left subclavian artery stenosis in patients scheduled for left internal mammary artery oronary artery bypass grafting. Catheterization and Cardiovascular Interventions, 2016, 87, 579-588.	0.7	12
150	The interval between carotid artery stenting and open heart surgery is related to perioperative complications. Catheterization and Cardiovascular Interventions, 2016, 87, 564-569.	0.7	2
151	Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution andÂAbsorption Kinetics. Journal of the American College of Cardiology, 2016, 67, 2249-2258.	1.2	40
152	Costs and Benefits Associated With Transradial Versus Transfemoral Percutaneous Coronary Intervention in China. Journal of the American Heart Association, 2016, 5, .	1.6	30
153	CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention. Thrombosis Research, 2016, 147, 108-114.	0.8	10
154	Symptom-Onset-To-Balloon Time, ST-Segment Resolution and In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in China: From China Acute Myocardial Infarction Registry. American Journal of Cardiology, 2016, 118, 1334-1339.	0.7	19
155	Heart-type Fatty Acid Binding Protein in the Assessment of Acute Pulmonary Embolism. American Journal of the Medical Sciences, 2016, 352, 557-562.	0.4	21
156	New strategies for improving stem cell therapy in ischemic heart disease. Heart Failure Reviews, 2016, 21, 737-752.	1.7	34
157	Impact of Operator Experience andÂVolume on Outcomes After LeftÂMainÂCoronary Artery PercutaneousÂCoronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 2086-2093.	1.1	97
158	The efficacy of renal artery stent combined with optimal medical therapy in patients with severe atherosclerotic renal artery stenosis. Current Medical Research and Opinion, 2016, 32, 3-7.	0.9	7
159	Coronary Artery Bypass Graft Surgery andÂPercutaneous Coronary Interventions in Patients With Unprotected Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2016, 9, 1102-1111.	1.1	42
160	The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. American Heart Journal, 2016, 175, 193-201.e3.	1.2	95
161	Green tea consumption and risk of cardiovascular and ischemic related diseases: A meta-analysis. International Journal of Cardiology, 2016, 202, 967-974.	0.8	105
162	Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis: Two-year results. International Journal of Cardiology, 2016, 205, 117-123.	0.8	35

#	Article	IF	CITATIONS
163	Simultaneous Bilateral vs Unilateral Carotid Artery Stenting. Journal of Endovascular Therapy, 2016, 23, 258-266.	0.8	9
164	Coronary Catheterization and Percutaneous Coronary Intervention in China. JAMA Internal Medicine, 2016, 176, 512.	2.6	72
165	Management and Outcomes Among Chinese Hospitalized Patients With Established Cardiovascular Disease or Multiple Risk Factors. Angiology, 2016, 67, 168-173.	0.8	4
166	Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention. Platelets, 2016, 27, 75-79.	1.1	17
167	AMPK-mediated cardioprotection of atorvastatin relates to the reduction of apoptosis and activation of autophagy in infarcted rat hearts. American Journal of Translational Research (discontinued), 2016, 8, 4160-4171.	0.0	16
168	Safety and efficacy of a novel abluminal grooveâ€filled biodegradable polymer sirolimusâ€eluting stent for the treatment of de novo coronary lesions: Twoâ€year results from a prospective patientâ€level pooled analysis of TARGET trials. Catheterization and Cardiovascular Interventions, 2015, 85, 734-743.	0.7	10
169	Cardiac Microvascular Barrier Function Mediates the Protection of Tongxinluo against Myocardial Ischemia/Reperfusion Injury. PLoS ONE, 2015, 10, e0119846.	1.1	21
170	Impact of Body Mass Index on the Clinical Outcomes after Percutaneous Coronary Intervention in Patients ≥75 Years Old. Chinese Medical Journal, 2015, 128, 638-643.	0.9	7
171	Effect of Final Kissing Balloon Dilatation after One-stent Technique at Left-main Bifurcation. Chinese Medical Journal, 2015, 128, 733-739.	0.9	9
172	A Comparison of the Transradial and Transfemoral Approaches for the Angiography and Intervention in Patients with a History of Coronary Artery Bypass Surgery. Chinese Medical Journal, 2015, 128, 762-767.	0.9	9
173	Thyroid Status, Cardiac Function, and Mortality in Patients With Idiopathic Dilated Cardiomyopathy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3210-3218.	1.8	49
174	Comparison between oneâ€stent versus twoâ€stent technique for treatment of left main bifurcation lesions: A large singleâ€center data. Catheterization and Cardiovascular Interventions, 2015, 85, 1132-1138.	0.7	22
175	Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2015, 66, 2298-2309.	1.2	228
176	The analysis of related factors of ventricular aneurysm formation in patients with acute myocardial infarction in northwest of China. International Journal of Cardiology, 2015, 181, 50-52.	0.8	2
177	Association of green tea consumption with risk of coronary heart disease in Chinese population. International Journal of Cardiology, 2015, 179, 275-278.	0.8	24
178	The clinical, angiographic and prognosis characteristics of elderly patients with acute ST-segment elevation myocardial infarction—The first elderly STEMI population study in northwest of China. International Journal of Cardiology, 2015, 179, 326-328.	0.8	5
179	A Comparison of Transradial and Transfemoral Approaches for Percutaneous Coronary Intervention in Elderly Patients Based on a Propensity Score Analysis. Angiology, 2015, 66, 448-455.	0.8	8
180	Comparison of Short- and Medium-Term Clinical Outcomes between Transradial Approach and Transfemoral Approach in a High-Volume PCI Heart Center in China. PLoS ONE, 2015, 10, e0118491.	1.1	5

#	Article	IF	CITATIONS
181	Plasma miR-122 and miR-3149 Potentially Novel Biomarkers for Acute Coronary Syndrome. PLoS ONE, 2015, 10, e0125430.	1.1	37
182	Intravenous administration of atorvastatin-pretreated mesenchymal stem cells improves cardiac performance after acute myocardial infarction: role of CXCR4. American Journal of Translational Research (discontinued), 2015, 7, 1058-70.	0.0	25
183	Remote Ischemic Preconditioning Reduces Perioperative Cardiac and Renal Events in Patients Undergoing Elective Coronary Intervention: A Meta-Analysis of 11 Randomized Trials. PLoS ONE, 2014, 9, e115500.	1.1	51
184	Percutaneous Transluminal Angioplasty for Symptomatic Pulmonary Stenosis in Takayasu Arteritis. Journal of Rheumatology, 2014, 41, 1856-1862.	1.0	22
185	Is Being an Elderly Woman a Risk Factor for Worse Outcomes After Percutaneous Coronary Intervention? A Large Cohort Study From One Center. Angiology, 2014, 65, 596-601.	0.8	1
186	Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials. Atherosclerosis, 2014, 233, 568-578.	0.4	21
187	Atorvastatin treatment improves the effects of mesenchymal stem cell transplantation on acute myocardial infarction: The role of the RhoA/ROCK/ERK pathway. International Journal of Cardiology, 2014, 176, 670-679.	0.8	36
188	Simvastatin-enhanced expression of promyogenic nuclear factors and cardiomyogenesis of murine embryonic stem cells. Vascular Pharmacology, 2014, 60, 8-16.	1.0	5
189	The efficacy and safety of transradial percutaneous coronary intervention VS transfemoral percutaneous coronary intervention for ST-segment elevation myocardial infarction patients: A meta-analysis. International Journal of Cardiology, 2014, 177, 483-488.	0.8	6
190	Statin is a two-edged sword in liver enzyme. International Journal of Cardiology, 2014, 171, e18.	0.8	1
191	One-year outcomes of percutaneous renal denervation for the treatment of resistant hypertension: the first Chinese experience. Chinese Medical Journal, 2014, 127, 1003-7.	0.9	1
192	Atorvastatin induces autophagy of mesenchymal stem cells under hypoxia and serum deprivation conditions by activating the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Chinese Medical Journal, 2014, 127, 1046-51.	0.9	9
193	Transradial versus transfemoral percutaneous coronary intervention in elderly patients: a systematic overview and meta-analysis. Chinese Medical Journal, 2014, 127, 1110-7.	0.9	3
194	Statins and stem cell modulation. Ageing Research Reviews, 2013, 12, 1-7.	5.0	34
195	Atorvastatin Enhance Efficacy of Mesenchymal Stem Cells Treatment for Swine Myocardial Infarction via Activation of Nitric Oxide Synthase. PLoS ONE, 2013, 8, e65702.	1.1	72
196	A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention, 2013, 9, 75-83.	1.4	60
197	LONG-TERM OUTCOMES OF COMPLETE VERSUS INCOMPLETE REVASCULARISATION AFTER DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH MULTIVESSEL CORONARY DISEASE. Heart, 2012, 98, E158.2-E158.	1.2	0
198	Autophagy Activation: A Novel Mechanism of Atorvastatin to Protect Mesenchymal Stem Cells from Hypoxia and Serum Deprivation via AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. Stem Cells and Development, 2012, 21, 1321-1332.	1.1	152

#	Article	IF	CITATIONS
199	Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating amp-activated protein kinase. International Journal of Cardiology, 2011, 153, 311-316.	0.8	43
200	Rosuvastatin Treatment Activates JAK-STAT Pathway and Increases Efficacy of Allogeneic Mesenchymal Stem Cell Transplantation in Infarcted Hearts. Circulation Journal, 2011, 75, 1476-1485.	0.7	60
201	Transradial Versus Transfemoral Method of Percutaneous Coronary Revascularization for Unprotected Left Main Coronary Artery Disease: Comparison of Procedural and Late-Term Outcomes. JACC: Cardiovascular Interventions, 2010, 3, 1035-1042.	1.1	52
202	Prevalence of transradial coronary angiography and intervention in China: Report from the Transradial coronary intervention Registration Investigation in China (TRI-China). International Journal of Cardiology, 2010, 145, 246-247.	0.8	15
203	Combined Therapy With Simvastatin and Bone Marrow–Derived Mesenchymal Stem Cells Increases Benefits in Infarcted Swine Hearts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2076-2082.	1.1	110
204	Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: Comparison with bare-metal stent implantation. American Heart Journal, 2008, 155, 553-561.	1.2	37
205	Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. European Heart Journal, 2008, 29, 1578-1590.	1.0	112
206	Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATPchannel. European Journal of Heart Failure, 2007, 9, 30-36.	2.9	24
207	Comparison of immediate and followup results between transradial and transfemoral approach for percutaneous coronary intervention in true bifurcational lesions. Chinese Medical Journal, 2007, 120, 539-44.	0.9	5
208	Comparison of in-hospital and long-term outcomes between a Cypher stent and a Taxus stent in Chinese diabetic patients with coronary artery disease. Chinese Medical Journal, 2007, 120, 1868-73.	0.9	0
209	Comparison of Metoprolol With Low, Middle and High Doses of Carvedilol in Prevention of Postinfarction Left Ventricular Remodeling in Rats International Heart Journal, 2003, 44, 979-988.	0.6	13
210	Identification and Validation of Candidate Gene Module Along With Immune Cells Infiltration Patterns in Atherosclerosis Progression to Plaque Rupture via Transcriptome Analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	8